Regardless of the sequential decrease in Current Liabilities, during the third quarter 2026, Quick Ratio deteriorated to 10.75 below Celldex Therapeutics Inc 's average Quick Ratio.

Within In Vitro & In Vivo Diagnostic Substances industry Celldex Therapeutics inc booked the highest Quick Ratio than Celldex Therapeutics Inc in the third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 253 to 399.

Explain Quick Ratio?
How much Cash & cash equivalents CLDX�s has?
What are CLDX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/CLDX/financial-strength

https://api.csimarket.com/api/v1/companies/CLDX/fundamentals

https://api.csimarket.com/api/v1/companies/CLDX/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

CLDX Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	30.24 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	11.5 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	10.75	Subscribe	Subscribe	Subscribe	Subscribe
CLDX's Total Ranking	# 399	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-1.32 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-9.37 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
In Vitro & In Vivo Diagnostic Substances Industry	# 1
Healthcare Sector	# 135
Overall Market	# 399

Quick Ratio Statistics
High	Average	Low
31.34	12.34	3.15
(Mar 31 2024)		(Dec 31 2010)

Financial Statements
Celldex Therapeutics Inc 's Current Liabilities	$ 61 Millions	Visit CLDX's Balance sheet
Celldex Therapeutics Inc 's Cash & cash equivalent	$ 650 Millions	Visit CLDX's Balance sheet
Source of CLDX's Sales		Visit CLDX's Sales by Geography

Cumulative Celldex Therapeutics Inc 's Quick Ratio

CLDX's Quick Ratio for the trailling 12 Months

CLDX Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	48.6 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	-10.5 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	10.42	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 4005	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	6.68 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	2.95 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to CLDX Financial Strength Comparisons >> Go to Compare CLDX Quick Ratio to its Competitors

On the trailing twelve months basis Due to decrease in Current Liabilities in the Q3 2026 to $60.52 millions, cumulative Quick Ratio decreased to 10.42 above the CLDX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within In Vitro & In Vivo Diagnostic Substances industry 14 other companies have achieved higher Quick Ratio than Celldex Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 3235 to 4005.

Explain Quick Ratio?
How much Cash & cash equivalents CLDX�s has?
What are CLDX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the In Vitro & In Vivo Diagnostic Substances Industry	# 15
Healthcare Sector	# 900
Within the Market	# 4005

trailing twelve months Quick Ratio Statistics
High	Average	Low
4.2	2.14	0.65
(Dec 31 2013)		(Dec 31 2025)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within In Vitro & In Vivo Diagnostic Substances Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Achieve Life Sciences Inc	14.81	$ 201.518 Millions	$ 13.610 Millions
Celldex Therapeutics inc	10.75	$ 650.319 Millions	$ 60.517 Millions
Intellia Therapeutics Inc	5.90	$ 474.110 Millions	$ 80.306 Millions

Date modified: 2026-11-09T18:44:14+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.